Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 425-220-8
CAS number: 5945-33-5
Acute Oral and Acute dermal toxicity studies.Acute inhalation study is waived due to physical properties of the substance
Acute oral and dermal studies were performed in male and female rats
with Fyrolflex BDP. No mortalities were observed in either sex at 2000
mg/kg following oral administration. No mortalities were observed in
either sexes following dermal application of 2000 mg/kg. No signs of
systemic toxicity were noted during clinical observations in both
studies. No abnormalities were noted during necropsy in both studies.
Fyrolflex BDP is not classified for acute oral or dermal toxicity.
Based on the experimantal results in the Acute Oral and Dermal toxicity
studies, Fyrolflex BDP is not classified for Acute toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Questo sito web si avvale di cookie affinché possiate usufruire della migliore esperienza sui nostri siti web.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again